BIOMAT Database Logo BIOMAT Database Logo

Teicoplanin-resistant coagulase-negative staphylococci. 1987

W Brumeitt, and J M Hamilton-Miller, and L O Neville

UI MeSH Term Description Entries
D003030 Coagulase Enzymes that cause coagulation in plasma by forming a complex with human PROTHROMBIN. Coagulases are produced by certain STAPHYLOCOCCUS and YERSINIA PESTIS. Staphylococci produce two types of coagulase: Staphylocoagulase, a free coagulase that produces true clotting of plasma, and Staphylococcal clumping factor, a bound coagulase in the cell wall that induces clumping of cells in the presence of fibrinogen. Staphylocoagulase,Staphylococcal Clumping Factor,Clumping Factor (Staphylococcal),Staphylococcus aureus clone pSCa2 of Coagulase,Staphylococcus aureus strain 213 of Coagulase,Staphylococcus aureus strain 8325-4 of Coagulase,Clumping Factor, Staphylococcal,Factor, Staphylococcal Clumping,Staphylococcus aureus strain 8325 4 of Coagulase
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D006020 Glycopeptides Proteins which contain carbohydrate groups attached covalently to the polypeptide chain. The protein moiety is the predominant group with the carbohydrate making up only a small percentage of the total weight. Glycopeptide
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D013203 Staphylococcal Infections Infections with bacteria of the genus STAPHYLOCOCCUS. Infections, Staphylococcal,Staphylococcus aureus Infection,Staphylococcal Infection,Staphylococcus aureus Infections
D013210 Staphylococcus A genus of gram-positive, facultatively anaerobic, coccoid bacteria. Its organisms occur singly, in pairs, and in tetrads and characteristically divide in more than one plane to form irregular clusters. Natural populations of Staphylococcus are found on the skin and mucous membranes of warm-blooded animals. Some species are opportunistic pathogens of humans and animals.
D017334 Teicoplanin Lipoglycopeptide antibiotic from Actinoplanes teichomyceticus active against gram-positive bacteria. It consists of five major components each with a different fatty acid moiety. Teichomycin,Targocid,Teichomycin A2

Related Publications

W Brumeitt, and J M Hamilton-Miller, and L O Neville
Teicoplanin-resistant coagulase-negative staphylococci.
January 1987, Lancet (London, England),
W Brumeitt, and J M Hamilton-Miller, and L O Neville
Emergence of teicoplanin-resistant coagulase-negative staphylococci.
July 1996, Journal of clinical microbiology,
W Brumeitt, and J M Hamilton-Miller, and L O Neville
[Isolation of coagulase-negative teicoplanin-resistant staphylococci].
June 1990, Presse medicale (Paris, France : 1983),
W Brumeitt, and J M Hamilton-Miller, and L O Neville
Susceptibility of coagulase-negative staphylococci to teicoplanin.
February 1996, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
W Brumeitt, and J M Hamilton-Miller, and L O Neville
Teicoplanin-resistant coagulase-negative staphylococcus.
November 1986, Lancet (London, England),
W Brumeitt, and J M Hamilton-Miller, and L O Neville
Teicoplanin-resistant coagulase-negative staphylococcus.
October 1986, Lancet (London, England),
W Brumeitt, and J M Hamilton-Miller, and L O Neville
Percentages and distributions of teicoplanin- and vancomycin-resistant strains among coagulase-negative staphylococci.
May 1990, Antimicrobial agents and chemotherapy,
W Brumeitt, and J M Hamilton-Miller, and L O Neville
Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of staphylococci.
January 1998, Antimicrobial agents and chemotherapy,
W Brumeitt, and J M Hamilton-Miller, and L O Neville
Nosocomial meningitis due to teicoplanin-resistant coagulase-negative staphylococci complicating ventriculoperitoneal shunt insertion in children.
October 2005, Journal of chemotherapy (Florence, Italy),
W Brumeitt, and J M Hamilton-Miller, and L O Neville
Resistant coagulase-negative staphylococci in hospital patients.
January 1987, The Journal of hospital infection,
Copied contents to your clipboard!